Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Aarvik Therapeutics
Deal Size : $100.0 million
Deal Type : Collaboration
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
Details : ArriVent will be responsible for clinical development and commercialization of a novel ADC molecule, for oncology indications, that relies on the unique modular platform developed by Aarvik.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 15, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Aarvik Therapeutics
Deal Size : $100.0 million
Deal Type : Collaboration
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Alphamab Oncology
Deal Size : $615.5 million
Deal Type : Collaboration
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Details : Through the collaboration, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications.
Brand Name : Undiclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Alphamab Oncology
Deal Size : $615.5 million
Deal Type : Collaboration
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
ArriVent Announces Pricing of Upsized Initial Public Offering
Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA
Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : InnoCare Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
InnoCare and ArriVent Announce Clinical Development Collaboration
Details : Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in...
Brand Name : ICP-189
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : InnoCare Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2022
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Brand Name : AST2818
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?